Treatment practices for metastatic pancreatic cancer: Can we deliver an appropriately efficacious and safe regimen in Indian patients?

Simple item page
dc.contributor.authorRamaswamy, Ananten_US
dc.contributor.authorOstwal, Vikasen_US
dc.contributor.authorGoel, Aloken_US
dc.contributor.authorBhargava, Prabhaten_US
dc.contributor.authorSujay, Srinivasen_US
dc.contributor.authorSanyo, Dsouzaen_US
dc.contributor.authorShailesh, V Shrikhandeen_US
dc.date.accessioned2020-01-02T06:27:59Z
dc.date.available2020-01-02T06:27:59Z
dc.date.issued2018-04
dc.description.abstractINTRODUCTION: The median overall survival (mOS) in metastatic pancreatic cancers (PCs) hovers between 6 months to 11 months. MATERIALS AND METHODS: The study is a retrospective analysis of metastatic PC patients who were evaluated from August 2013 to August 2016 in the Department of Gastrointestinal (GI) Medical Oncology, Tata Memorial Hospital (TMH). RESULTS: Out of 218 patients, 24 patients (11%) were not planned for chemotherapy and referred to the Department of Palliative Care for further supportive care. One hundred and fifty-three patients received palliative chemotherapy in TMH with median age of 56 years (range: 23–79), male (60.1%), and nonresident in Maharashtra (60.1%). Regimens used most commonly were gemcitabine–nab-paclitaxel in 60 patients (39.2%), gemcitabine–erlotinib in 25 patients (16.3%), and modified FOLFIRINOX in 21 patients (13.7%). A total of 58 patients (43%; n = 135) had Grade 3/4 toxicities. As of cutoff date for the analysis of outcomes, 139 patients (90.8%) patients had ceased first-line chemotherapy, due to radiologically proven progressive disease (PD) in 89 patients (64%), repeated Grades 3 and 4 adverse events in 26 patients (18.7%), and clinically PD in 18 patients (12.9%). With a median follow-up of 278 days, the mOS was 217 days (95% confidence interval [CI]: 175–258), and the median event-free survival was 125 days (95% CI: 107–122). CONCLUSION: Dose modifications for chemotherapy are required commonly when treating metastatic PC, with common reasons for dose reduction being toxicities, Eastern Cooperative Oncology Group performance status >=2, and low albumin levels. Studies evaluating logistic and financial aspects of treating metastatic PC with chemotherapy in India are warranted.en_US
dc.identifier.affiliationsDepartment of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtraen_US
dc.identifier.citationRamaswamy Anant, Ostwal Vikas, Goel Alok, Bhargava Prabhat, Sujay Srinivas, Sanyo Dsouza, Shailesh V Shrikhande. Treatment practices for metastatic pancreatic cancer: Can we deliver an appropriately efficacious and safe regimen in Indian patients?. Indian Journal of Cancer. 2018 Apr; 55(2): 137-143en_US
dc.identifier.issn0019-509X
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/190335
dc.languageenen_US
dc.publisherIndian Cancer Societyen_US
dc.relation.issuenumber2en_US
dc.relation.volume55en_US
dc.source.urihttps://dx.doi.org//10.4103/ijc.IJC_552_17en_US
dc.titleTreatment practices for metastatic pancreatic cancer: Can we deliver an appropriately efficacious and safe regimen in Indian patients?en_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijoc2018v55n2p137.pdf
Size:
753.72 KB
Format:
Adobe Portable Document Format
Download
Collections
Indian Journal of Cancer